Faxed prescriptions will	only be accepted from			s must bring an original prescription to the pharmacy, and cannot fax these referral forms to Senderra. Prescriber: NPI:							
		Purified Cortrophin Gel Enrollment Form									
		Linomin			Supervising Physician:				NPI:		
SENDERRA		Physician Offices Call:		Address:					Tax ID:		
Specialty Pharmacy		855-460-7928		Phone: Fax:							
3712 E. Plano Parkway Plano, TX 75074	Fax: 888-777-5645		Contact:								
This prescription form is to be sent & received via fax											
Name: PATIENT INFORMATION Name: DOB: SS#:											
☐ M ☐ F ☐ Trans				State:							
Street: City: Phone: Alt. Phone:								1.14			
Phone:	Alt. F			English U Spanish U Other:							
PRESCRIPTION Refill Ship by: / / SHIP TO: Patient's Home Doctor's Office Other:											
Drug — Reilli	Ship by: / / SHIP TO: U Patient's Home U Doctor's Office U Other: Directions & Quantity						Refills				
	☐ 1mL multi-dose vial		Dose:	Route of Administration: Schedul		ile/Frequency:	Quantity of Vials:				
				□ _{IM} □ _{SQ}							
Purified Cortrophin® Ge	— SITE Matt-dosc viai				34						
	□ 80 units/mL Pre-fill		Ro	ute of Administration:	Schedule/Frequency:		Quantity of Syringes:				
					□ _{SQ}						
	40 units/0.5mL Pre-filled syringe										
Supplies	Sharps Container Syringe	☐ 1cc syringe ☐ 23 G x 1" ☐ 25 G x 5/8"						Quantity: Quantity: Quantity:			
	Needles										
MEDICAL INFORMATION											
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES & LAB WORK PERTINENT TO THERAPY											
PREVIOUS T	HERAPIES:	Trie	ed & Failed (Duration):		Not Tolerated: □			С	ontraindication:		
M06.9 Rheumatoid Arthritis, unspecified											
L20.9 Atopic Dermatitis, unspecified M33.90 Dermatopolymyositis, unspecified, organ involvement unspecified											
□ M33.20 Polymyositis, organ involvement unspecified □ L40.9 Psoriasis, unspecified □ M45.9 Ankylosing Spondylitis of unspecified sites in spine □ M32.10 Systemic lupus erythematosus, organ or system involvement unspecified											
■ M45.9 Ankylosing Spondylitis of unspecified sites in spine ■ M32.10 Systemic lupus erytnematosus, organ or system involvement unspecified ■ M80.00 Unspecified Juvenile Rheumatoid Arthritis of unspecified site											
L40.50 Arthropathic Psoriasis, unspecified (Psoriatic Arthritis)											
Other:											
G35 Multiple Sclerosis Is Cortrophin to be used to treat an acute exacerbation? Yes No (If yes, please provide date of onset://) Other:											
R80.9 Proteinuria (Please indicate etiology):					Glomerular Sclerosis (FSGS) LN) IgA Nephropathy (IgAN) Membranous Nephropathy (MN)						
Lupus Nephritis (LN) Other: Membranous Nephropathy (MN)											
□ H10.45 Other chronic allergic conjunctivitis □ H16.9 Keratitis, unspecified											
H20.9 Iridocyclitis (Uveitis), unspecified											
□ H30.90 Unspecified Chorioretinal inflammation, unspecified eye (Choroiditis) □ H30.009 Chorioretinitis and Focal Retinochoroiditis											
Allergies:											
Allergies.			Histo	ry of C	orticosteroid Use	_''					
	A corticosteroid was tried with the following response(s): A corticosteroid was not tried due to the following response(s):										
☐ Patient hypersensitive or allergic ☐ Patient intolerant to corticosteroids					□ Corticosteroid use is contraindicated for this patient □ Patient has known intolerance to corticosteroids						
Corticosteroid use failed, but same response not expected with Cortrophin Gel				☐ Intravenous access is not possible for this patient							
☐ Previous corticosteroids tried were: ☐ Oral ☐ IV					Other:			_			
Additional Clinical Information:											
D					ON TRAINING		П				
	eived pen and injection t		PRE	SCRIB	to provide injection trainin				coordinate injection		
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.											
Prescriber:						Date	e: /	/_			
CONFIDENTIALITY NOTICE IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.											
distribute, or copy this fax. Pleas	e notify the sender immediately	if you have rec	ceived this document in error and	then dest	roy this document immediately.		, , , , , , , , , , , , , , , , , ,		, / 04 0.10410		